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Introduction
Colorectal cancer (CRC) remains a formidable global health 
burden and represents one of the most frequent tumors 
in both genders [1]. Prognosis and treatment decisions 
are still largely based on the TNM system, but despite 
revisions to improve its predictive and prognostic value, 
this system is still under debate [2, 3]. Among the strong-
est prognostic factors is lymph node status, with node- 
positivity usually indicating a less favorable prognosis and 
a need for adjuvant chemotherapy after surgery. However, 
even the role of lymph nodes has been debated [4], as 
this is a fairly rough quality indicator and fails to avoid 
under- and overtreatment. The growing evidence for the 
role of genetic variability in cancer behavior and disease 
outcome has therefore called for a stratified approach to 
cancer care based on specific molecular traits.
The last decades have shed light on several important 
molecular mechanisms of CRC, allowing for useful clinical 
subtyping and making CRC a useful model for the 
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Abstract
Microsatellite instability (MSI) is associated with better prognosis in colorectal 
cancer (CRC). Elevated microsatellite alterations at selected tetranucleotides 
(EMAST) is a less- understood form of MSI. Here, we aim to investigate the 
role of EMAST in CRC±MSI related to clinical and tumor- specific characteristics. 
A consecutive, population- based series of stage I–III colorectal cancers were 
investigated for MSI and EMAST using PCR primers for 10 microsatellite mark-
ers. Of 151 patients included, 33 (21.8%) had MSI and 35 (23.2%) were EMAST+, 
with an overlap of 77% for positivity, (odds ratio [OR] 61; P < 0.001), and 
95% for both markers being negative. EMAST was more prevalent in colon 
versus rectum (86% vs. 14%, P = 0.004). EMAST+ cancers were significantly 
more frequent in proximal colon (77 vs. 23%, P = 0.004), had advanced t- stage 
(T3–4 vs. T1–2 in 94% vs. 6%, respectively; P = 0.008), were larger (≥5 cm 
vs. <5 cm in 63% and 37%, respectively; P = 0.022) and had poorly differenti-
ated tumor grade (71 vs. 29%, P < 0.01). Furthermore, EMAST+ tumors had 
a higher median number of harvested lymph nodes than EMAST− (11 vs. 9 
nodes; P = 0.03). No significant association was found between EMAST status 
and age, gender, presence of distant metastases or metastatic lymph nodes, and 
overall survival. A nonsignificant difference toward worse survival in node- 
negative colon cancers needs confirmation in larger cohorts. EMAST+ cancers 
overlap and share features with MSI+ in CRC. Overall, survival was not influ-
enced by the presence of EMAST, but may be of importance in subgroups such 
as node- negative disease of the colon.
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understanding of cancer initiation and progression [5]. 
Microsatellite instability (MSI) is one such important 
feature and has been associated with better prognosis and 
tumor- specific characteristics [6]. First described in the 
hereditary proportion of CRCs and associated with the 
Lynch syndrome, MSI also occurs in about 15% of  sporadic 
CRCs.
MSI represents a pathway of carcinogenesis that runs 
parallel to that of chromosomal instability and is of 
acknowledged prognostic, predictive, and potentially thera-
peutic relevance [6]. Instability at mono- and dinucleotide 
microsatellites is today included in the clinical and bio-
logical definition of MSI, for example, by the Bethesda 
criteria for MSI testing and definitions [7]. However, in 
a rapidly increasing number of studies, instability at tetra-
nucleotides has been described and considered as a par-
ticular subtype of MSI over a wide range of tumor types, 
from those originating in the aerodigestive organs to the 
gastrointestinal tract [8]. This newly described form of 
microsatellite instability was named “elevated microsatellite 
alterations at selected tetranucleotides” (EMAST).
In CRC, several recent findings have suggested potential 
molecular mechanisms underlying EMAST [9–13]. 
However, the clinicopathological relevance and difference 
with “canonical” MSI in CRC is still poorly investigated. 
Thus, we aim to investigate the role of EMAST in rela-
tion to clinical- and tumor- specific data, including MSI 
status, and analyze the effect on survival.
Patients and Methods
Study cohort
The study cohort represents consecutive patients with 
non- metastatic colorectal cancer (stage I–III) who were 
<75 years of age at diagnosis and who entered into an 
in- hospital, surgeon- led systematic surveillance program 
per national standards at the time[14], and as previously 
described at the time [15–17]. All included patients pre-
sented between 1996 and 1999 and underwent curative 
surgery for colorectal cancer at the Department of 
Gastrointestinal Surgery, Stavanger University Hospital, 
Norway. Clinicopathological information was recorded, 
and follow- up was updated as of July 23rd, 2011, thus 
providing up to 15 years follow- up after surgery [16].
Notably, as this cohort represents patients who were 
eligible for a systematic surveillance program at the time 
of surgery, patient >75 years and stage III (pN+) not fit 
for adjuvant chemotherapy were excluded [15, 16]. Patients 
with stage III disease and who were otherwise fit were 
offered adjuvant chemotherapy according to national 
guidelines at the time, typically consisting of 5- fluorouracil 
and leucovorin (5- FU/LV) [18]. Thus, elderly patients and 
those deemed unfit for adjuvant chemotherapy or, in the 
case of distant recurrence, deemed not fit for a second 
surgery were not included in this cohort.
From the above- described initial cohort (n = 196), there 
were 151 specimens (98 from colon and 53 from rectum) 
with available tissue for DNA extraction from formalin- 
fixed, paraffin- embedded (FFPE) tumor and tumor- free 
resection margin tissues for this study.
Ethics
The study was approved as a quality assurance project 
(REK#2010/3414) by the Regional Ethics Committee of 
the Health Trust of Western Norway.
Gross and histopathological assessment
All tumors were assessed for gross and histomorphological 
characteristics, and staged according to TNM- classifications 
per routine at the time. For the current analyses, a patholo-
gist reviewed the slides to ensure appropriate selection of 
tumor tissue and blocks with appropriate high tumor 
content (>50% viable tumor tissue) per block used for 
DNA extraction.
DNA extraction and fragment analysis
Following inspection by an experienced pathologist, four 
consecutive tumor and tumor- free 10 μm sections were cut 
from FFPE blocks for DNA extraction, using the Tissue 
DNA E.Z.N.A. kit (Omega BioTech®, Norcross, GA, USA) 
according to manufacturer’s instructions. DNA extracted 
from tumor tissue and their corresponding normal tissue 
(from surgical resection margins) was then PCR- amplified 
with five tetranucleotide microsatellites primer pairs (EMAST: 
D20S85, D20S82, D9S242, D8S321, MYCL1, 5` fluorescently 
labeled) and five mono- and dinucleotide microsatellite 
primer pairs (MSI: NR- 27, NR- 21, NR- 24, BAT- 25, BAT- 26, 
5` fluorescently labeled). PCR conditions were as follows: 
initial denaturation step of 5′ at 95°C, followed by 37 cycles 
of denaturation (30″ at 95°C), annealing (90″ at 55°C), and 
extension (30″ at 72°C), and concluded by a final elonga-
tion step (30′ at 60°C). The primers sequences, expected 
amplicon sizes and fluorescent dyes are provided in Table 1.
The PCR products were analyzed for fragment lengths 
on a 3130xl GeneticAnalyzer (Applied Biosystems, Foster 
City, CA, USA), with GeneMapper v3.7 software (Applied 
Biosystems, Foster City, CA, USA). Tumor samples were 
compared with their corresponding normal samples. Those 
showing any number of extra peaks at ±4n (n ≠ 0) (tetra-
nucleotides markers, EMAST), and/or ±1n or 2n (n ≠ 0) 
(mono- and dinucleotide markers, respectively, MSI) were 
scored as unstable for that marker.
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Definition of EMAST and MSI
To detect EMAST either direct sequencing or fragment 
analysis are generally used, with most laboratories adopt-
ing a panel of five tetranucleotide polymorphic markers 
(at least two unstable markers to score EMAST positivity). 
In CRC, up to seven microsatellite markers have been 
reportedly used, with EMAST considered present 
(EMAST+) when at least one marker was found unstable. 
In this study, we adopt the most used definitions of at 
least two out of five tetranucleotide markers unstable to 
confirm EMAST.
Samples showing instability in at least two out of five 
markers (40%) were recorded as EMAST- positive and/or 
microsatellite instability- high (MSI- H), while instability of 
one out of five markers was scored as EMAST- negative 
and/or microsatellite instability- low (MSI- L). If no unstable 
markers were found, the specimens were considered as 
microsatellite- stable (MSS). MSI analysis was done as 
previously described [17, 19]. Two investigators completed 
the scoring process independently, blinded to each other’s 
results. Discordance among investigators’ scoring was 
addressed by rerunning the samples by PCR followed by 
rescoring.
Statistical analysis
All statistical analyses were performed on IBM® SPSS® 
Statistics for Mac and Windows, version 23 (Armonk, 
NY, USA). Continuous variables were tested for normality 
by the Shapiro–Wilks test and for comparison by Mann–
Whitney U test. Relationships between categorical variables 
were investigated via Fischer’s exact and Chi- square tests, 
as appropriate. Overall and recurrence- free survival was 
assessed by Kaplan–Meier analysis using the log rank test. 
All tests are two- tailed and statistical significance was set 
at P < 0.050.
Results
Of the 151 patients included, the age and gender distri-
bution together with other clinicopathological character-
istics are presented in Table 2. The frequencies of MSI- H 
and EMAST were of 33 and 35 (22 and 23%) out of 
151 patients included, respectively (Table 2). Seventy- seven 
percent of EMAST cases (27/35) were also MSI- H for an 
odds ratio (OR) of 61.9, (95% CI: 19.8–193.3; P < 0.001). 
The distribution of MSI- and EMAST- positive tumors 
across the different sections of the large intestine are 
presented in Figure 1. Dual positive cases (both EMAST+ 
and MSI+; n = 27), were predominantly located in the 
colon (n = 25; 92.6%) compared to rectum (n = 2; 7.8%). 
The ascending and transverse colon had the highest number 
of dual positive cases, for seven and eight each (25.9% 
and 29.6%, respectively).
Of the 53 rectal and 98 colon tumors, five (9.4%) and 
30 (30.6%) were positive for EMAST, respectively (cumu-
lative: 86% colon, 14% rectum, P = 0.004). EMAST+ 
tumors had a higher prevalence in proximal versus distal 
colon (77% vs. 23%, P = 0.004) and were also associated 
with advanced t- stage in both EMAST (OR 6.0, 95% CI: 
1.4–26.6; P = 0.008) and MSI cancers (OR 5.5, 95% CI: 
1.3–24.5; P = 0.013), respectively.
EMAST+ tumors had a higher median number of har-
vested lymph nodes than EMAST– (11 vs. 9 nodes; 
P = 0.029; Fig. 2), but no difference in the number of 
lymph nodes positive for tumor cells infiltration was found.
A total of 38 (25.2%) patients developed metastases 
and died from CRC in this cohort. Neither EMAST nor 
MSI predicted risk of development of distant metastases, 
nor was EMAST predictive for disease- specific and for 
overall long- term survival in this cohort (Fig. 3A). However, 
on subanalyses of colon cancers only, as these harbor a 
higher frequency of EMAST- positive cases in comparison 
with rectal cancers, a nonsignificant difference in 
Table 1. Name, size, fluorescent label, and primer sequences of the microsatellite markers investigated.
Marker Amplicon size (bp) Label Forward primer Reverse primer
EMAST primers
MYCL1 181 6- FAM TGGCGAGACTCCATCAAAG CCTTTTAAGCTGCAACAATTTC
D20S85 146 NED GAGTATCCAGAGAGCTATTA ATTACAGTGTGAGACCCTG
D8S321 237 VIC GATGAAAGAATGATAGATTACAG ATCTTCTCATGCCATATCTGC
D20S82 249 6- FAM GCCTTGATCACACCACTACA GTGGTCACTAAAGTTTCTGCT
D9S242 178 PET GTGAGAGTTCCTTCTGGC ACTCCAGTACAAGACTCTG
MSI primers
NR- 27 89 VIC AACCATGCTTGCAAACCACT CGATAATACTAGCAATGACC
NR- 21 110 6- FAM GAGTCGCTGGCACAGTTCTA CTGGTCACTCGCGTTTACAA
NR- 24 128 PET GCTGAATTTTACCTCCTGAC ATTGTGCCATTGCATTCCAA
BAT- 25 152 VIC TACCAGGTGGCAAAGGGCA TCTGCATTTTAACTATGGCTC
BAT- 26 182 NED CTGCGGTAATCAAGTTTTTAG AACCATTCAACATTTTTAACCC
EMAST, Elevated microsatellite alterations at selected tetranucleotides; MSI, Microsatellite instability.
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long- term cancer- specific survival was noted, particularly 
for the node- negative (stage I–II) patients (Fig. 3B). 
Furthermore, these depicted an apparent worse outcome 
for EMAST+ (Fig. 3C) compared to microsatellite- stable 
cancers, and those with either one form of microsatellite 
instability only.
Discussion
In this cohort study, we found EMAST+ CRC to largely 
overlap with features associated with MSI+ cancers, includ-
ing a predominant location in the colon, association with 
low- grade histology, larger tumor size, and advanced depth 
of growth (T3- 4). Despite a higher number of lymph nodes 
sampled for EMAST+ cancers, there was no difference in 
the number of malignant nodes (neither in actual numbers 
nor in the rate of pN+ cases) and no statistically significant 
effect on survival could be found. The nonsignificant yet 
apparent difference in survival curves between groups 
depicted in Figure 3 with a trend toward reduced survival 
in EMAST+ cancers, specifically for node- negative colon 
cancers needs verification in larger cohorts.
Several findings need comment in this study. We 
found a significantly lower prevalence of EMAST in 
Table 2. Characteristics of patient and tumors according to EMAST status 
n = 151
n (%) P n (%) P
EMAST− EMAST+ MSS MSI
Age (years) <65 58 (73.4) 21 (26.6) 0.299 57 (72.2) 22 (27.8) 0.062
≥65 58 (80.6) 14 (19.4) 61 (84.7) 11 (15.3)
Gender M 73 (79.3) 19 (20.7) 0.358 75 (81.5) 17(18.5) 0.210
F 43 (72.9) 16 (27.1) 43 (72.9) 16 (27.1)
Tumor location Colon 68 (69.4) 30 (30.6) 0.003 69 (70.4) 29 (29.6) 0.002
Rectum 48 (90.6) 5 (9.4) 49 (92.5) 4 (7.5)
Tumor stage T1–2 31 (93.9) 2 (6.1) 0.008 31 (93.9) 2 (6.1) 0.013
T3–4 85 (72.0) 33 (28.0) 87 (73.7) 31 (26.3)
Tumor grade Poor/mucinous 10 (50.0) 10 (50.0) 0.002 8 (40.0) 12 (60.0) <0.001
Moderate/well 106 (80.9) 25 (19.1) 110 (84.0) 21 (16.0)
Tumor size1 ≥5 cm 44 (68.8) 20 (31.2) 0.022 43 (67.2) 21 (32.8) <0.001
<5 cm 67 (84.8) 12 (15.2) 72 (91.1) 7 (8.9)
EMAST, Elevated microsatellite alterations at selected tetranucleotides; MSI, microsatellite instability; MSS, microsatellite stable. Values highlighted in 
bold indicate significance level of p < 0.05.
1Size missing in eight samples (5.3%)
Figure 1. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and microsatellite instability (MSI) cancer distribution in colon and 
rectum. EMAST denotes elevated microsatellite alterations at selected tetranucleotides; MSI denotes microsatellite instability.
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our sample (23%) when compared with the majority 
of the studies available in the literature, reporting EMAST 
frequencies in CRC ranging between 33% and 64.8% 
[9, 12, 13, 20–22]. As previously reviewed [8], such 
variation could be due to the type and number of 
markers and the thresholds used in EMAST analyses, 
with the highest (60% and over) frequencies reported 
by groups using a less stringent approach to define 
EMAST [22]. The degree of overlap between MSI cases 
and EMAST (77% in this study), is in line with studies 
that report between 67% and 100% overlap, and thus, 
the selected cohort should be within the range of vari-
ation as reported elsewhere in the literature. The fact 
that most, and in some cases all, the MSI- H tumors 
are also EMAST+, and that the latter tumors are gen-
erally more prevalent, could suggest a cause–consequence 
relationship. It is also interesting to see the prognostic 
features shared by MSI and EMAST- positive cancers 
(Table 2), including larger size, poor differentiation, 
and depth of growth. While these features would nor-
mally be associated with a worse prognosis, some emerg-
ing data suggest that MSI and possibly EMAST cancers 
may be associated with specific immune reactions and 
T- lymphocyte infiltrations associated with a more favora-
ble outcome [10].
Neither EMAST nor MSI was found to significantly 
correlate with survival (neither overall nor recurrence- free). 
Of the four studies investigating survival, specifically in 
EMAST+ and EMAST− tumors currently available in the 
scientific literature, two found no significant difference 
in overall survival [9, 12]. However, one study of meta-
static CRC observed that MSI- H tumors that also displayed 
EMAST+ had significantly worse overall survival, compared 
to non- EMAST cancers with MSI- H [13]. This is in line 
with the nonsignificant findings in this study, albeit in 
early- stage colon cancers. A further study found a sig-
nificantly reduced recurrence- free survival (RFS) in 
EMAST+ cancers, when compared to MSI- H, but the 
degree of overlapping EMAST/MSI was not disclosed [23]. 
In both studies the MSI- H/EMAST- group was composed 
of a limited number of individuals.
As demonstrated in the current cohort, both MSI and 
EMAST produce larger tumors. If this is because of EMAST/
MSI tumors developing more quickly due to a much 
higher rate of mutation that a defective MMR system 
confers to the nest of cancer- initiating cells remains specu-
lative, but warrants investigation. Conversely, EMAST/MSI 
may be genetic events that occur as a side effect of other 
drivers of carcinogenesis, or merely reflects a high turnover 
and induction of genetic errors during rapid growth of 
the tumor cells. Some studies look into mechanisms of 
EMAST [11, 22, 24, 25], and point to a role of hypoxia, 
oxidative stress, and DNA repair mechanisms [26]. 
However, overall data are scarce and further understand-
ing is thus needed.
Some limitations should be considered when comparing 
our study cohort with other patient series. First, we included 
only patients who were <75 years and who entered a 
systematic surveillance program after surgery [15], and 
excluded elderly patients or those with comorbidities who 
were unfit for adjuvant chemotherapy or unlikely to toler-
ate metastatic surgery. Thus, we have introduced a clinical 
bias towards younger, fitter patients with stage I–III colo-
rectal cancers in this series. This should be taken into 
account when interpreting our findings, as the results 
could thus not apply to a more general patient cohort 
with higher age and that frequently included stage IV 
cancers. The latter may also be the reason for a nonsig-
nificant trend in the analyses, as others have found EMAST 
status of importance in stage IV and metastatic disease 
[13, 23, 27]. For example, Venderbosch et al.[13] found 
a statistically significant difference in survival between 
patients with and without EMAST. Notably, the included 
patients all came from clinical phase III trials (the Dutch 
CAIRO and CAIRO2 studies) of metastatic CRC, and 
thus all patients in the cohort had an unfavorable outcome 
[13]. Indeed, EMAST may be an accumulated effect of 
worse biology, higher mutational load, and thus play a 
Figure 2. Number of lymph nodes found in the resected specimen, 
according to elevated microsatellite alterations at selected 
tetranucleotides (EMAST) status. P- value for difference in median 
number between groups.
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Figure 3. Cancer- specific survival according to elevated microsatellite alterations at selected tetranucleotides (EMAST) status, stages, and location. 
(A) overall cancer- specific survival for all colorectal stage I–III cancers, with no significant difference, yet a somewhat poorer outcome in EMAST + 
cancers. (B) cancer- specific survival for colon cancers only, again with nonsignificant poorer survival in EMAST+ patients. (C) outcome for node- 
negative (stage I–II) colon cancers, split into patients with microsatellite stable (MSS; blue line), microsatellite instability (MSI)- /EMAST+ (green), 
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more prominent role in biology in late stage (e.g., meta-
static disease) compared with early (stage I–III) disease. 
Evidence that EMAST may act as a potential biological 
modulator among the different types of molecular classes 
(e.g., microsatellite instability, epigenetics, and chromo-
somal instability) involved in CRC have been proposed 
[28], and is further suggested in a combined series of 
metastatic disease in CRC [27]. Thus, EMAST may be 
more specific for tumor biology and disease outcome in 
late- stage groups [29], such as colorectal liver metastasis, 
but further studies need to corroborate these findings. 
Notably, several aspects in clinical practice, including a 
higher frequency of metastatic surgery and extending 
adjuvant chemotherapy to elderly patients have occurred 
since the late 1990s, so clinical differences in practice 
may have introduced selection and outcome bias in this 
cohort compared with more recent cohorts. However, 
long- term follow- up would not be possible with more 
recent cohorts, so the true eventual outcome of the patients 
(e.g., death from disease or other cause; still alive with 
no evidence of disease etc.) is likely to have been captured 
accurately in this series. The small cohort prevents from 
robust subgroup analysis and these should therefore be 
interpreted with caution. An apparent prognostic role in 
stage I–II CRC warrants further investigation. Finally, how 
EMAST should be determined lacks firm definition in 
the current literature, possibly explaining why our results 
deviate from others based on the choice of defined mark-
ers and numbers used for positivity. This methodological 
issue must be solved through further clarification of bio-
logical mechanisms and ability for robust and valid tests 
of selected markers or panels of markers.
While the clinical role of EMAST in CRC is still 
being investigated, the biological implications of recent 
investigations may yield findings of new mechanisms 
that have a clinical relevance in selected patients at 
both extremes of presentation, either as early cancers 
or as metastatic disease. Thus, further investigation into 
the biological mechanisms and their potential clinical 
implications should be pursued. Whether EMAST is an 





 1. Brenner, H., M. Kloor, and C. P. Pox. 2014. Colorectal 
cancer. Lancet 383:1490–1502.
 2. Quirke, P., G. T. Williams, N. Ectors, A. Ensari, F. 
Piard, and I. Nagtegaal. 2007. The future of the TNM 
staging system in colorectal cancer: time for a debate? 
Lancet Oncol. 8:651–657.
 3. Lea, D., S. Haland, H. R. Hagland, and K. Søreide. 
2014. Accuracy of TNM staging in colorectal cancer: a 
review of current culprits, the modern role of 
morphology and stepping- stones for improvements in 
the molecular era. Scand. J. Gastroenterol. 
49:1153–1163.
 4. Veen, T., B. S. Nedrebø, K. Stormark, J. S. Søreide, 
H. Kørner, and K. Søreide. 2013. Qualitative and 
quantitative issues of lymph nodes as prognostic factor 
in colon cancer. Dig. Surg. 30:1–11.
 5. Grady, W. M., and J. M. Carethers. 2008. Genomic and 
epigenetic instability in colorectal cancer pathogenesis. 
Gastroenterology 135:1079–1099.
 6. Sinicrope, F. A., and D. J. Sargent. 2012. Molecular 
pathways: microsatellite instability in colorectal cancer: 
prognostic, predictive, and therapeutic implications. 
Clin. Cancer Res. 18:1506–1512.
 7. Umar, A., C. R. Boland, J. P. Terdiman, S. Syngal, A. 
de la Chapelle, J. Rüschoff, et al. 2004. Revised 
Bethesda Guidelines for Hereditary Nonpolyposis 
Colorectal Cancer (Lynch Syndrome) and Microsatellite 
Instability. J. Natl Cancer Inst. 96:261–268.
 8. Watson, M. M., M. Berg, and K. Soreide. 2014. 
Prevalence and implications of elevated microsatellite 
alterations at selected tetranucleotides in cancer. Br. J. 
Cancer 111:823–827.
 9. Yamada, K., S. Kanazawa, J. Koike, H. Sugiyama, C. 
Xu, K. Funahashi, et al. 2010. Microsatellite instability 
at tetranucleotide repeats in sporadic colorectal cancer 
in Japan. Oncol. Rep. 23:551–561.
10. Lee, S. Y., K. Miyai, H. S. Han, D. Y. Hwang, M. K. 
Seong, H. Chung, et al. 2012. Microsatellite instability, 
EMAST, and morphology associations with T cell 
infiltration in colorectal neoplasia. Dig. Dis. Sci. 
57:72–78.
11. Tseng-Rogenski, S. S., H. Chung, M. B. Wilk, S. Zhang, 
M. Iwaizumi, and J. M. Carethers. 2012. Oxidative 
stress induces nuclear- to- cytosol shift of hMSH3, a 
potential mechanism for EMAST in colorectal cancer 
cells. PLoS ONE 7:e50616.
12. Hamaya, Y., C. Guarinos, S. S. Tseng-Rogenski, M. 
Iwaizumi, R. Das, R. Jover, et al. 2015. Efficacy of 
Adjuvant 5- Fluorouracil Therapy for Patients with 
EMAST- Positive Stage II/III Colorectal Cancer. PLoS 
ONE 10(5):e0127591.
13. Venderbosch, S., Vliet S. van Lent-van, A. F. de Haan, 
M. J. Ligtenberg, M. Goossens, C. J. Punt, et al. 2015. 
EMAST is associated with a poor prognosis in 
microsatellite instable metastatic colorectal cancer. PLoS 
ONE 10:e0124538.
14. Søreide, K., J. H. Traeland, P. J. Stokkeland, T. 
Glomsaker, J. A. Søreide, and H. Kørner. 2012. 
1587© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
EMAST in Colorectal CancerM. M. Watson et al.
Adherence to national guidelines for surveillance after 
curative resection of nonmetastatic colon and rectum 
cancer: a survey among Norwegian gastrointestinal 
surgeons. Colorectal Dis. 14:320–324.
15. Kørner, H., K. Søreide, P. J. Stokkeland, and 
J. A. Søreide. 2005. Systematic follow- up after curative 
surgery for colorectal cancer in Norway: a population- 
based audit of effectiveness, costs, and compliance. J. 
Gastrointest. Surg. 9:320–328.
16. Veen, T., K. Stormark, B. S. Nedrebø, M. Berg, 
J. A. Søreide, H. Kørner, et al. 2015. Long- Term 
Follow- Up and Survivorship After Completing 
Systematic Surveillance in Stage I- III Colorectal Cancer: 
who Is Still at Risk? J. Gastrointest. Cancer 46:259–266.
17. Søreide, K., A. Slewa, P. J. Stokkeland, B. van Diermen, 
E. A. Janssen, J. A. Søreide, et al. 2009. Microsatellite 
instability and DNA ploidy in colorectal cancer: 
potential implications for patients undergoing systematic 
surveillance after resection. Cancer 115:271–282.
18. Dahl, O., O. Fluge, E. Carlsen, J. N. Wiig, H. E. 
Myrvold, B. Vonen, et al. 2009. Final results of a 
randomised phase III study on adjuvant chemotherapy 
with 5 FU and levamisol in colon and rectum cancer 
stage II and III by the Norwegian Gastrointestinal 
Cancer Group. Acta Oncol. 48:368–376.
19. Søreide, K. 2011. High- fidelity of five 
quasimonomorphic mononucleotide repeats to high- 
frequency microsatellite instability distribution in 
early- stage adenocarcinoma of the colon. Anticancer Res. 
31:967–971.
20. Devaraj, B., A. Lee, B. L. Cabrera, K. Miyai, L. Luo, 
S. Ramamoorthy, et al. 2010. Relationship of EMAST 
and microsatellite instability among patients with rectal 
cancer. J. Gastrointest. Surg. 14:1521–1528.
21. Lee, S. Y., H. Chung, B. Devaraj, M. Iwaizumi, 
H. S. Han, D. Y. Hwang, et al. 2010. Microsatellite 
alterations at selected tetranucleotide repeats are 
associated with morphologies of colorectal neoplasias. 
Gastroenterology 139:1519–1525.
22. Haugen, A. C., A. Goel, K. Yamada, G. Marra, T. P. 
Nguyen, T. Nagasaka, et al. 2008. Genetic instability 
caused by loss of MutS homologue 3 in human 
colorectal cancer. Cancer Res. 68:8465–8472.
23. Garcia, M., C. Choi, H. R. Kim, Y. Daoud, Y. Toiyama, 
M. Takahashi, et al. 2012. Association between recurrent 
metastasis from stage II and III primary colorectal 
tumors and moderate microsatellite instability. 
Gastroenterology 143:48–50. e1.
24. Tseng-Rogenski, S. S., Y. Hamaya, D. Y. Choi, and 
J. M. Carethers. 2015. Interleukin 6 Alters Localization 
of hMSH3, Leading to DNA Mismatch Repair Defects in 
Colorectal Cancer Cells. Gastroenterology 148:579–589.
25. Campregher, C., G. Schmid, F. Ferk, S. Knasmüller, V. 
Khare, B. Kortüm, et al. 2012. MSH3- deficiency initiates 
EMAST without oncogenic transformation of human 
colon epithelial cells. PLoS ONE 7:e50541.
26. Carethers, J. M., M. Koi, and S. S. Tseng-Rogenski. 
2015. EMAST is a Form of Microsatellite Instability 
That is Initiated by Inflammation and Modulates 
Colorectal Cancer Progression. Genes (Basel) 6:185–205.
27. Koi, M., M. Garcia, C. Choi, H. R. Kim, J. S. Koike, 
H. Hemmi, et al. 2016. Microsatellite Alterations With 
Allelic Loss at 9p24.2 Signify Less- Aggressive Colorectal 
Cancer Metastasis. Gastroenterology. doi: http://dx.doi.
org/10.1053/j.gastro.2015.12.032. [Epub ahead of print].
28. Carethers, J. M., and B. H. Jung. 2015. Genetics and 
Genetic Biomarkers in Sporadic Colorectal Cancer. 
Gastroenterology 149:1177–1190. e3.
29. Søreide, K., M. M. Watson, and H. R. Hagland. 2016. 
Deciphering the molecular code to colorectal liver 
metastasis biology through microsatellites and allelic 
loss: the good, the bad and the ugly. Gastroenterology. 
doi: http://dx.doi.org/10.1053/j.gastro.2016.02.060. [Epub 
ahead of print].
